A Case of Non-Small Cell Lung Cancer With Pituitary Dysfunction Revealed 10 Months After the Single Administration of Nivolumab

Japanese Journal of Lung Cancer - Japan
doi 10.2482/haigan.58.980
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japan Lung Cancer Society

Related search

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Fatal Necrotizing Encephalopathy After Treatment With Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature

Frontiers in Immunology
AllergyImmunology
2018English

Real-World Data on Nivolumab Treatment of Non-Small Cell Lung Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2016English

Acute Interstitial Nephritis in a Patient With Non-Small Cell Lung Cancer Under Immunotherapy With Nivolumab

Case Reports in Nephrology
2019English

Tuberculosis Infection in a Patient Treated With Nivolumab for Non-Small Cell Lung Cancer: Case Report and Literature Review

Frontiers in Oncology
Cancer ResearchOncology
2019English

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Nivolumab-Induced Severe Acute Kidney Injury With a Long Latent Phase in a Patient With Non-Small-Cell Lung Cancer: A Case Report

Clinical Case Reports
Medicine
2018English

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

OncoImmunology
OncologyAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy